Collection

A Means to an ENDS: The Uncertainty of ENDS Use and Cardiovascular Disease From Human Research to Basic Science Mechanisms

Submission status
Open
Open for submission from
13 April 2024
Submission deadline
31 December 2024
After almost 2 decades of Electronic Nicotine Delivery Systems (ENDS; including electronic cigarettes, heat-not-burn (HNB), and electronic hookah products) presence in the world marketplace, uncertainty persists regarding the long-term cardiovascular disease (CVD) consequences of ENDS use. In order to address this gap in knowledge regarding the cardiovascular disease risk of ENDS use or of exposures to ENDS-derived aerosols, we are posting a ‘call for papers’ in a special issue of Cardiovascular Toxicology. This issue is dedicated to being a showcase of the emerging data on this critical issue. We desire to minimize the time between the emergence of CVD risk (e.g., of ENDS use) and the administration of well-founded regulatory policy by providing a resource of the best current basic and applied ENDS research. Given the history of the damaging effects of conventional cigarette smoking on the human cardiovascular system -- there is an urgent need to reveal cardiovascular toxicities of ENDS. For this we invite all varieties of research papers on ENDS effects from basic science projects to human studies covering all endpoints related to CVD outcomes including thrombosis, vascular dysfunction, and cardiac arrythmias in cell and animal studies to human panel, cross-sectional and prospective studies. As emerging data has developed on the effects of in utero and pre-pregnancy exposures on fetal outcomes, and revealed transplacental effects, we encourage research in this area as well – again, both from animal and human studies.

Editors

  • I.M. Olfert I.M. Olfert  &

    I.M. Olfert

    Dr. Olfert is Professor at West Virginia University in the Department of Human Performance, Division of Exercise Physiology and the Department of Physiology, Pharmacology & Toxicology. He received his Doctorate of Philosophy degree in Physiology & Pharmacology from Loma Linda University, Loma Linda, CA, USA, and post-doctoral training in pulmonary physiology and vascular biology at University of California San Diego. He has been named Fellow of the American Heart Association (FAHA) by the Council on Basic Cardiovascular Sciences, and Fellow of the American Physiology Society (FAPS).

  • F. Khasawneh F. Khasawneh

    F. Khasawneh

    Dr. Fadi T Khasawneh received his PhD in Pharmacology from the University of Illinois in 2007. He joined Texas A&M University in 2020 as Head of the Pharmaceutical Science Department. His research focuses on the pathogenesis of thrombotic disorders in the context of platelet biology, novel tobacco products & exposures, and sepsis. He is a standing-member of the HTBT study section, and previously chaired the VA's HEMA study section. He is also a Fellow of the American Heart Association, and has previously served as Chair for the Cardiovascular Pharmacology Division of the American Society for Pharmacology and Experimental Therapeutics.

Articles (3 in this collection)